HomeNewsBusinessMarketsDAILY VOICE | Smart money to move to large private banks, autos, construction, consumption: Dhananjay Sinha of JM Financial

DAILY VOICE | Smart money to move to large private banks, autos, construction, consumption: Dhananjay Sinha of JM Financial

Sinha expects the downside will be limited from here on, and he still maintains a target of 15700 on the Nifty by end of the year.

May 19, 2021 / 11:26 IST
Story continues below Advertisement

Dhananjay Sinha, Managing Director & Chief – Strategist, JM Financial Institutional Securities Limited, is of the view that if the second wave is contained either through effective vaccination or natural immunisation, then the strength in the market should continue.

Sinha has over 20 years of experience in Indian financial markets. Prior to joining JM Financial, Sinha worked with Systematix Group, IDFC Securities, Emkay Global Financial Services, Centrum Broking, Infosys, ICICI Bank, JM Morgan Stanley, Times Bank etc.

Story continues below Advertisement

In an interview with Moneycontrol's Kshitij Anand, Sinha said that the downside will be limited from here on, and he still maintains a target of 15700 on the Nifty by end of the year.

Edited excerpts:-

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show